Drug Approval | July 18, 2022
Orchid Pharma updates on PLI scheme benefits for its subsidiary
The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"
The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
The company plans to execute both these tenders at their API manufacturing unit located at Savli, Gujarat, India.
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
Plant is part of the company's CAD $30 million capital investment in the site
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Nippon Express has provided a pharmaceutical distribution platform with strict temperature control in two ranges -- 2 C to 8 C
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
Subscribe To Our Newsletter & Stay Updated
